FLGT Share Price Performance
US$26.72
8.30 (45.06%)
25.8% undervalued intrinsic discount
US$36.00
Fair Value
Price US$26.72
AnalystHighTarget US$36.00
AnalystLowTarget US$21.00
AnalystConsensusTarget US$33.67
Fair ValueUS$36.00
Share Pricen/a
Fulgent Genetics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
FLGT Community Narratives
AN
Fair Value US$36 25.8% undervalued intrinsic discount
Rapid Genomic Medicine Advances Will Reshape The Diagnostics Landscape
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$21 27.2% overvalued intrinsic discount
Regulatory Costs And Fierce Competition Will Choke Genomic Testing
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$33.67 20.6% undervalued intrinsic discount
Enhanced Whole Genome Sequencing Will Open New Global Markets
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Rapid Genomic Medicine Advances Will Reshape The Diagnostics Landscape
Key Takeaways Rapid expansion, proprietary technology, and early adoption in genomics position the company for sustained organic growth, first-mover advantage, and robust margin improvements. Automation, managed care expansion, and differentiated therapeutic pipelines enable superior scalability, recurring revenue stability, and significant upside in high-margin markets.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$36
25.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
10.71% p.a.
Profit Margin
5.45%
Future PE
58.49x
Price in 2028
US$43.82
Enhanced Whole Genome Sequencing Will Open New Global Markets
Key Takeaways Broadened clinical endorsements, new service launches, and international certifications strengthen market position, drive revenue growth, and diversify global reach. Operational efficiencies and expanded managed care contracts boost volume growth, enhance gross margins, and establish a sustainable foundation for future profitability.Read more
32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$33.67
20.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
10.04% p.a.
Profit Margin
5.45%
Future PE
55.73x
Price in 2028
US$40.98
Regulatory Costs And Fierce Competition Will Choke Genomic Testing
Key Takeaways Heightened regulatory, privacy, and payer pressures threaten revenue growth, margin stability, and market size, potentially limiting the company's profitability and future expansion. Heavy spending on development and expansion efforts may not yield proportional returns due to fierce competition, rapid technological change, and ongoing industry commoditization.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$21
27.2% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
10.39% p.a.
Profit Margin
5.46%
Future PE
35.56x
Price in 2028
US$25.11
Trending Discussion
Recently Updated Narratives
AN
FLGT: Improved Profit Outlook And Pipeline Progress Will Support Upside Potential
Fair Value: US$36 25.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FLGT: Raised 2025 Guidance And Trial Progress Will Support Bullish Outlook
Fair Value: US$33.67 20.6% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Costs And Fierce Competition Will Choke Genomic Testing
Fair Value: US$21 27.2% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Fulgent Genetics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.39
- 41.24%
- -13.62%
- 0.2%
About FLGT
- Founded
- 2011
- Employees
- 1313
- CEO
- WebsiteView website
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
